scispace - formally typeset
H

Hyoun Woo Kang

Researcher at Dongguk University

Publications -  68
Citations -  1303

Hyoun Woo Kang is an academic researcher from Dongguk University. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 15, co-authored 57 publications receiving 1068 citations. Previous affiliations of Hyoun Woo Kang include New Generation University College & Seoul National University.

Papers
More filters
Journal ArticleDOI

Visceral Obesity and Insulin Resistance as Risk Factors for Colorectal Adenoma: A Cross-Sectional, Case―Control Study

TL;DR: Visceral obesity was found to be an independent risk factor of colorectal adenoma, and insulin resistance was associated with the presence of colOREctalAdenoma.
Journal ArticleDOI

Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.

TL;DR: A biosimilar of infliximab, CT‐P13 (Remsima®) has the potential to reduce treatment costs and enhance access to biological therapy for inflammatory bowel disease (IBD) patients, but long‐term clinical data are currently sparse.
Journal ArticleDOI

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

TL;DR: CT-P13 may have biosimilarity and interchangeability with its originator in inflammatory bowel disease and a large, randomized, double-blind, prospective study is needed.
Journal ArticleDOI

Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer

TL;DR: In stool DNA test for SDC2 methylation by LTE-qMSP comparing CRC patients with various stages (I to IV) and precancerous lesions and healthy subjects (n = 21) with healthy subjects, the result indicates that stool DNA-based SDC 2 methylation test by qMSP is a potential noninvasive diagnostic tool for early detection of CRC.
Journal ArticleDOI

Effect of probiotics on symptoms in korean adults with irritable bowel syndrome.

TL;DR: Choi et al. as mentioned in this paper designed a prospective double-blind randomized placebo-controlled clinical study to assess their effects in Korean adults with Irritable bowel syndrome (IBS).